王悦,张文婷,张丽娜,姜凤超

• 1:华中科技大学同济医学院药学院

摘要(Abstract)：

细胞周期素依赖性激酶-5(cylin-dependent kinase-5,Cdk5)作为细胞周期素依赖性激酶家族成员之一,其生理作用主要表现为影响神经细胞的正常发育和维持有丝分裂后神经细胞的功能及骨架结构。Cdk5催化底物磷酸化功能的失调与一些神经退行性疾病有着密切的关系。该文重点对Cdk5介导的Alzheimer病的病理过程及已报道的Cdk5抑制剂进行综述,探讨该靶点药物开发中存在的问题及可能的解决办法。

关键词(KeyWords)： 细胞周期素依赖性激酶-5;Alzheimer病;抑制剂;构效关系

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王悦,张文婷,张丽娜,姜凤超

参考文献(References)：

• [1]COHEN P.Protein kinases——the major drug targets of the twenty.first century?[J].Nat Rev Drug Dis.cov,2002,1(4):309.315.
• [2]SRIDHAR J,AKULA N,PATTABIRAMAN N.Se.lectivity and potency of cyclin.dependent kinase in.hibitors[J].AAPS J,2006,8(1):204.221.
• [3]TARRICONE C,DHAVAN R,PENG J,et al.Struc.ture and regulation of the CDK5.p25nck5acomplex[J].Mol Cell,2001,8(3):657.669.
• [4]DHAVAN R,TSAI L H.A decade of Cdk5[J].Nat Rev Mol Cell Biol,2001,2(10):749.759.
• [5]CRUZJ C,TSAI L H.Cdk5deregulation in the path.ogenesis of Alzheimer′s disease[J].Trends Mol Med,2004,10(9):452.458.
• [6]BALLATORE C,LEE V M,TROJANOWSKI J Q.Tau.mediated neurodegeneration in Alzheimer′s dis.ease and related disorder[J].Nat Rev Neurosci,2007,8(9):663.672.
• [7]LEE M S,KWON Y T,LI M,et al.Neurotoxicity in.duces cleavage of p35to p25by calpain[J].Nature,2000,405(6784):360.364.
• [8]MAZANETZ M P,FISCHER P M.Untangling tau hyperphosphorylation in drug design for neurodegen.erative diseases[J].Nat Rev Drug Discov,2007,6(6):464.479.
• [9]CRUZ J C,TSENG H C,GOLDMAN J A,et al.Ab.errant Cdk5activation by p25triggers pathological e.vents leading to neurodegeneration and neurofibril.lary tangles[J].Neuron,2003,40(3):471.483.
• [10]NOBLE W,OLM V,TAKATA K,et al.Cdk5is a key factor in tau aggregation and tangle formationin vivo[J].Neuron,2003,38(4):555.565.
• [11]ALVAREZ A,TORO R,CACEES A,et al.Inhibi.tion of tau phosphorylating protein kinase Cdk5pre.ventsβ.amyloid.induced neuronal death[J].FEBS Lett,1999,459(3):421.426.
• [12]WEN Y,YU W H,MALONEY B,et al.Transcrip.tional regulation ofβ.secretase by p25/Cdk5leads to enhanced amyloidogenic processing[J].Neuron,2008,57(5):680.690.
• [13]MAPELLI M,MASSIMILIANO L,CROVACE C,et al.Mechanism of CDK5/p25binding by CDK inhib.itors[J].J Med Chem,2005,48(3):671.679.
• [14]METTEY Y,GOMPEL M,THOMAS V,et al.Aloisines,a new family of CDK/GSK.3inhibitors.SAR study,crystal structure in complex with CDK2,enzyme selectivity,and cellular effects[J].J Med Chem,2003,46(2):222.236.
• [15]DUCROT P,LEGRAVEREND M,GRIERSON D S.3D.QSAR CoMFA on cyclin.dependent kinase in.hibitors[J].J Med Chem,2000,43(22):4098.4108.
• [16]POLYCHRONOPOULOS P,MAGIATIS P,SKALTSOUNIS A L,et al.Structural basis for the synthesis of indirubins as potent and selective inhibi.tors of glycogen synthase kinase.3and cyclin.de.pendent kinases[J].J Med Chem,2004,47(4):935.946.
• [17]BEAUCHARD A,FERANDIN Y,FRERE S,et al.Synthesis of novel5.substituted indirubins as proteinkinases inhibitors[J].Bioorg Med Chem,2006,14(18):6434.6443.
• [18]ZHONG W,LIU H,KALLER M R,et al.Design and synthesis of quinolin.2(1H).one derivatives as potent CDK5inhibitors[J].Bioorg Med Chem Lett,2007,17(19):5384.5389.
• [19]RZASA R M,KALLER M R,LIU G,et al.Struc.ture.activity relationships of3,4.dihydro.(1H).quin.azolin.2.one derivatives as potential CDK5inhibitors[J].Bioorg Med Chem,2007,15(20):6574.6595.
• [20]HELAL C J,SANNER M A,COOPER C B,et al.Discovery and SAR of2.aminothiazole inhibitors of cyclin.dependent kinase5/p25as a potential treat.ment for Alzheimer′s disease[J].Bioorg Med Chem Lett,2004,14(22):5521.5525.
• [21]KUNICK C,LAUENROTH K,WIEKING K,et al.Evaluation and comparison of3D.QSAR CoMSIA models for CDK1,CDK5,and GSK.3inhibition by paullones[J].J Med Chem,2004,47(1):22.36.
• [22]AHN J S,RADHAKRISHNAN M L,MAPELLI M,et al.Defining Cdk5ligand chemical space with small molecule inhibitors of Tau phosphorylation[J].Chem Biol,2005,12(7):811.823.
• [23]SHARMA P,STEINBACH P J,SHARMA M,et al.Identification of substrate binding site of cyclin.de.pendent kinase5[J].J Biol Chem,1999,274(14):9600.9606.
• [24]AMIN N D,ALBERS W,PANT H C.Cyclin.de.pendent kinase5(Cdk5)activation requires interac.tion with three domains of p35[J].J Neurosci Res,2002,67(3):354.362.
• [25]ZHENG Y L,LI B S,AMIN N D,et al.A peptide derived from cyclin.dependent kinase activator(p35)specifically inhibits Cdk5activity and phosphoryla.tion of tau protein in transfected cells[J].Eur J Biochem,2002,269(18):4427.4434.